Introduction
============

T-cell acute lymphoblastic leukemia (T-ALL), which accounts for approximately 15% of childhood ALL and 25% of adult ALL cases [@b1], is characterized by a profound infiltration of the bone marrow with clonally rearranged T-cell receptor (TCR) [@b2] lymphoblasts [@b3] that stain positively for TdT and express CD1a, CD2, CD3, CD5, CD7, and CD8 [@b1]. An abnormal karyotype is usually detected in the lymphoblasts of 50--70% of T-ALL patients. The most common abnormalities are translocations causing the deregulation of transcription factors that are juxtaposed with a regulatory region of one of the TCR loci [@b1]. Currently, nearly 80% of pediatric T-ALL cases are cured with intensive chemotherapy [@b4]. However, adults with T-ALL fare much worse, and only approximately 50% survive for 5 years after being diagnosed [@b5].

In T-ALL, as in most other neoplasms, the neoplastic cell genome harbors somatic mutations. The number of somatic mutations in cancer cells ranges from less than 10 in neoplasms such as childhood ALL to more than 200 in melanoma or lung cancer [@b6]. Mutations in cancer cell genes are broadly categorized as those that provide malignant cells with a proliferative or survival advantage, collectively termed "driver" mutations, or those that do not, which are therefore termed "passenger" mutations. Similar terminology is used for genes: A driver gene is a mutated gene that provides the cell with a significant growth advantage [@b6]. The identification of driver genes is relatively easy if the frequency of mutations in a given gene is very high, as is the case for *TP53* in colon cancers [@b7]. In other cases, identifying driver mutations or driver genes might be challenging. Presumably, when an oncogene is recurrently mutated at the same amino acid position, this signifies a driver mutation, and driver mutations in tumor suppressor genes are those that cause protein truncation alterations [@b6].

Several somatic mutations have been recurrently identified in T-ALL including activating mutations of the *NOTCH1* gene, which encode a protein that is critical for early T-cell development [@b8], or in the *FBXW7* gene, a negative regulator of NOTCH1 [@b9]. Mutations in *FBXW7*, *PHF6*, *DNMT3A*, *RUNX1*, *JAK1*, and *WT1* as well as deletions of the *CDK2A/B* tumor suppressor genes have also been reported [@b10].

The cell surface interleukin (IL)-7 receptor-*α* (IL7R), present in lymphoid progenitor cells, is required for normal lymphocyte development [@b11]. IL7R forms heterodimers with IL-2R*γ* or with the cytokine receptor-like factor 2 (CRLF2) [@b12] and activates the JAK/STAT5 and the PI3K/Akt/mTOR signaling pathways [@b13]. *IL7R* mutations have been identified in malignant and nonmalignant diseases. Germ line loss-of-function mutations were found to be associated with the development of severe combined immunodeficiency [@b14]. Somatic mutations in *IL7R* have been identified in lung cancer patients where its functional significance is unknown, and mutations in IL7R are detected in 10% of pediatric T-ALL cases and in a few cases of pediatric B-ALL.

Because the distribution of mutations across a gene provides indications for its functional significance, we analyzed the distribution pattern of *IL7R* in pediatric ALL and lung cancer patients. Subsequently, we screened bone marrow samples of 35 adult patients with T-ALL for exon 6-*IL7R* mutations and did not detect a single case with mutations in exon6-*IL7R*. Our findings suggest that exon 6 *IL7R* mutations are driver events in childhood T-ALL that are not shared by adult T-ALL patients.

Materials and Methods
=====================

Patients
--------

Bone marrow cells were obtained from 35 patients 18 years or older with T-ALL treated at The University of Texas MD Anderson Cancer Center leukemia clinic from 2002 to 2010. Institutional Review Board approval and patients\' written informed consent were obtained. The clinical characteristics of the patients whose bone marrow samples were used in this study are presented in Table [1](#tbl1){ref-type="table"}.

###### 

Characteristics of the T-ALL pediatric cohort patients

  ----------------------------------- ------------------
  *N*                                 35
  Age                                 
   Median (range)                     32.5 (18--76)
  Gender                              
   Males *N* (%)                      25 (76%)
   Females *N* (%)                    8 (24%)
  Karyotype                           
   Normal                             16 (52%)
   Aberrant                           15 (48%)
   No data available                  4
  White blood cell count (×10^9^/L)   
   Median (range)                     8.7 (0.6--106)
  Platelet count (×10^9^/L)           
   Median (range)                     119 (11--612)
  Hemoglobin levels (g/L)             
   Median (range)                     10.6 (4.4--15.2)
  ----------------------------------- ------------------

Molecular analysis
------------------

To isolate low-density cells, bone marrow cells were fractionated using Histopaque 1077 (Sigma--Aldrich, St. Louis, MO). Genomic DNA was isolated by using a QIAamp DNA Blood Maxi Kit (Qiagen, Valencia, CA) according to the manufacturer\'s instructions. Briefly, bone marrow low-density cells were washed twice with cold phosphate-buffered saline, and 2 × 10^7^ cells were resuspended in 5 mL of phosphate-buffered saline. Cells were lysated with 12 mL of Buffer AL and digested with 500 *μ*L Qiagen Protease.

After the lysates were incubated for 10 min at 70°C, 10 mL of ethanol was added and mixed by inverting the tube several times. All of the lysates were loaded onto the QIAamp Maxi columns. The columns were washed with buffer AW1 and AW2. The genomic DNA was eluted with nuclease-free water, and 10--50 ng of genomic DNA was analyzed using polymerase chain reaction (PCR). PCR was performed by using a TaKaRa Hot Start PCR kit. The following primers directed at exon 6 of *IL7R* were used: forward: caactttcaggaaataataagtgg; reverse: taaattcgtgaaatgccttaatcc. The PCR products were run on an agarose gel, excised, purified with a QIAquick PCR purification kit (Qiagen), and sequenced. Sequencing of those purified PCR products was performed by SeqWright (Houston, TX).

Results and Discussion
======================

Different *IL7R-α* mutations induce dissimilar functions
--------------------------------------------------------

The catalog of somatic mutations in cancer (COSMIC) database (<http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/>) contains 127 *IL7R* somatic mutations. Most mutations are associated with the transcription of a full-length protein product including amino acid substitution mutations (32%), in-frame insertions (24%), and complex mutations (33%). None of the recurrent *IL7R* mutations are protein-truncating. *IL7R* mutations were found in squamous cell carcinoma (12/179; 6.7%) and adenocarcinoma (15/474; 3.2%) of the lung, pediatric T-ALL (64/665; 9.6%), B-ALL (13/276; 4.7%), and sporadically in other tumors. Remarkably, for each tissue, the type of mutations and the distribution across the *IL7R-α* gene are different. In lung tumors, substitution mutations are distributed across the entire *IL7R* gene in a seemingly random fashion. In childhood T-ALL, all *IL7R* mutations occur within a narrow 50-base pair interval at exon 6, encompassing in-frame insertions or deletion/insertion mutations.

The random distribution pattern of *IL7R* mutations across the IL7R gene in lung tumors versus the nonrandom distribution in pediatric ALL suggests a fundamental difference in the significance of *IL7R* mutation between the two entities: in tumors with a high mutation rate (e.g., lung tumor) there is a high probability of finding passenger, randomly inserted mutations. These are usually nonrecurrent, substitution mutations that are randomly spread across the gene. Conversely, when mutations are identified primarily in one or few intragenic sites, they probably confer a functional significance (Fig. [1](#fig01){ref-type="fig"}). Indeed, exon 6 *IL7R* mutations in pediatric T-ALL cases conferred cytokine-independent cell growth and promoted tumor cell transformation, confirming their functional significance as a "driver," gain-of-function mutation.

![Distribution of somatic *IL7R* mutations in different tumors. All mutations in *IL7R* are in-frame mutations, resulting in the translation of a full-length protein product. Upper panel: in lung tumors, substitution mutations are dispread across the entire gene appear usually only once and carry no functional significance. Middle panel: all mutations in childhood T-ALL are within the exon 6 narrow region of 50 base pairs. These mutations induce the production of a protein that is an oncogenic driver. Lower panel: in addition to mutations in exon 6, childhood B-ALL is characterized by serine-to-cysteine substitution in the extracellular domain, consistent with two driver oncogenic events, one common to both childhood B-ALL and T-ALL and one unique to childhood B-ALL. The figure was generated using the COSMIC database (<http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/>). COSMIC, catalog of somatic mutations in cancer.](cam40003-0550-f1){#fig01}

Two types of *IL7R* mutations have been identified in childhood ALL. The first type includes mutations affecting the transmembrane domain, whereby disulfide homodimerization of two mutant receptors induces constitutive activation of downstream signaling pathways, usually induced only upon ligand binding to the heterodimer receptor complex. This mutation is found in both childhood T-ALL and B-ALL. The second type includes a recurrent serine-to-cysteine substitution mutation at amino acid 185 in the extracellular *IL7R* domain. This mutation has been detected exclusively in B-ALL and almost always in association with mutations in the *CRLF2* gene [@b15], thereby suggesting that these mutations provide an advantage to B-lineage commitment, perhaps by inducing a weaker signal that preferentially activates only one signaling pathway. The *IL7R* insertion mutations at exon 6 were detected in both childhood T-ALL and B-ALL, whereas a recurrent serine-to-cysteine substitution at amino acid 185 (the S185C mutation in the *IL7R* extracellular domain) was identified exclusively in childhood B-ALL.

*IL7R* mutations are not detected in adult T-ALL
------------------------------------------------

Although activating mutations of *NOTCH1* have been detected in 70% of both pediatric and adult T-ALL cases [@b3],[@b10], significant age-related differences in the frequencies of other genetic alterations have been reported. For example, t(7;10)(q34;q24) and t(10;14)(q24;q11), both of which involve the translocation of the TCR in juxtaposition to the HOX11 transcription factor, occur in 7% of childhood T-ALL cases and 30% of adult T-ALL cases [@b16]. Similarly, a higher prevalence of *FBXW7* and *PHF6* mutations was reported in adult T-ALL [@b10],[@b17],[@b18].

Because the *IL7R* in-frame insertion mutation in exon 6 is a gain-of-function oncogenic driver mutation found in 10% of childhood T-ALL cases, we sought to determine whether this mutation is also present in adult T-ALL. A power calculation showed that analysis of 35 T-ALL samples has a power of 0.8 to detect an *IL7R* mutation if present in 10% or more of the samples. Therefore, we analyzed bone marrow aspirates from 35 adult patients with T-ALL for the presence of *IL7R* mutations at exon 6. *IL7R* insertion mutation was not detected in any of these cases. Whether age-dependent differences in the genetic makeup of T-ALL (signified by the lack of *IL7R* mutations) explain differences in response to therapy between adult and childhood T-ALL remains to be determined.
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